Thorey Solène, Behaghel Augustin, Sibeoni Jordan, Blanchet Corinne, Moro Marie Rose, Carretier Emilie, Ludot-Grégoire Maude
Groupe ERIC, UPB Colibry, Centre Hospitalier de Plaisir, 30 Avenue Marc Laurent, 78370, Plaisir, France.
Service Universitaire de Psychiatrie de L'Adolescent, Argenteuil Hospital Centre, 69 Rue du Ltc Prud'hon, 95100, Argenteuil, France.
J Eat Disord. 2025 Jul 21;13(1):146. doi: 10.1186/s40337-025-01327-6.
Olanzapine is commonly prescribed in Anorexia Nervosa, despite conflicting evidence regarding its efficacy and safety. This study aimed to complement existent quantitative by exploring the lived experiences of adolescents and parents with this treatment.
Ten adolescent girls and ten parents were interviewed in a single psychiatric department in Paris. Data saturation was achieved. We used semi-structured interviews enriched with narrative methods, including writing tasks and picture elicitation questions.
Four chronological meta-themes were identified: (1) Introduction of antipsychotic treatment with Olanzapine: rapid acceptance generating mixed feelings about the future. (2) The first few weeks of medication: Adolescents questioning alone the treatment after first intakes. (3) Taking note of the results during the initial few months of treatment. (4) Then what? Fears and doubts about the future.
The prescription of olanzapine was often perceived as a liminal stage-a transitional moment akin to a "rite of passage" in the trajectory of Anorexia Nervosa. For many adolescents, it represented an opportunity to assert autonomy and gain a sense of empowerment in their relationships with both the medical team and their parents. However, implicit concerns about weight gain as a side effect often became a core issue of miscommunication. These concerns should be openly addressed throughout the treatment process. Shortening the usual duration of olanzapine therapy may offer a constructive path toward reinforcing the therapeutic alliance and avoiding non-medical discontinuation.
尽管关于奥氮平的疗效和安全性存在相互矛盾的证据,但它在神经性厌食症的治疗中仍被广泛使用。本研究旨在通过探索青少年及其父母接受这种治疗的实际经历,对现有的定量研究进行补充。
在巴黎的一个精神科对10名青春期女孩和10名家长进行了访谈。达到了数据饱和。我们采用了丰富叙事方法的半结构化访谈,包括写作任务和图片引发问题。
确定了四个按时间顺序排列的元主题:(1) 引入奥氮平抗精神病治疗:迅速接受,对未来产生复杂的感受。(2) 用药的最初几周:青少年在首次服药后独自对治疗提出质疑。(3) 在治疗的最初几个月注意结果。(4) 然后呢?对未来的恐惧和疑虑。
奥氮平的处方通常被视为一个临界阶段——类似于神经性厌食症病程中的“通过仪式”的过渡时刻。对许多青少年来说,它代表了一个在与医疗团队和父母的关系中主张自主权并获得 empowerment感的机会。然而,作为副作用对体重增加的潜在担忧往往成为沟通不畅的核心问题。在整个治疗过程中应公开解决这些担忧。缩短奥氮平治疗的通常疗程可能为加强治疗联盟和避免非医学停药提供一条建设性的途径。